Navigation Links
Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant
Date:12/11/2007

SALT LAKE CITY, Dec. 11 /PRNewswire/ -- Amedica Corporation, an orthopedic implants company focused on silicon nitride ceramic technologies, announced today that the U.S. Food and Drug Administration has granted a Special 510(k) marketing clearance for Amedica's Valeo(TM) ceramic VBR spinal implant.

The Valeo VBR spinal implant is intended for vertebral body replacement to aid in surgical correction and stabilization of the thoracolumbar spine. The Valeo VBR incorporates Amedica's novel silicon nitride ceramic, which provides new functionalities compared to competing devices currently on the market. The implant is designed to restore the biomechanical integrity of the anterior, middle and posterior spine, even in the absence of fusion, for a prolonged period of time.

"This is an important alternative to spine implants made from titanium and PEEK, as well as bone grafts taken from human cadavers," said Darrel Brodke, M.D., Associate Professor in the Department of Orthopedic Surgery, University of Utah School of Medicine, and Chief of the Spine Service and Medical Director of the University Spine Center. "The ceramic Valeo VBR implants uniquely combine strength with bone apposition, and simultaneously provide the visualization compatibility necessary for medical diagnostic imaging."

"We are very pleased to have received this FDA clearance of our innovative silicon nitride ceramic Valeo VBR implant," said Ashok Khandkar, Ph.D., Chief Executive Officer of Amedica Corporation. "This is an important milestone for Amedica and we remain on track as we progress toward the expected launch of our lead Valeo products in the first half of 2008."

About Amedica

Amedica Corporation is an emerging orthopedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, high-performance spine and joint implants for the growing orthopedic device market. Its products under development include spine, reconstructive hip and knee implants that may represent a new standard of care in total joint implants based on superior durability, performance and safety.

Contact:

Reyn E. Gallacher

Chief Financial Officer

(801) 583-5100

ir@amedicacorp.com

http://www.amedicacorp.com


'/>"/>
SOURCE Amedica Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Amedicas Silicon Nitride Ceramic Bearing Technology Receives Prestigious HAP Paul Award for Use in Total Hip Arthroplasty
2. Amedica to Present at CIBC World Markets 18th Annual Healthcare Conference
3. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
4. DaVita Receives Civil Complaint
5. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
6. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
7. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
8. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
11. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different ... purpose as the host of the “Informed” series. The program focuses on many important ... series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: